BioSig Technologies, Inc. STEX Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by BioSig Technologies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioSig Technologies, Inc.'s total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioSig Technologies, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- BioSig Technologies, Inc. (STEX) reported total cash, cash equivalents, and restricted cash (inclusive) of $6.86M in Q1 2026.
- How has BioSig Technologies, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- BioSig Technologies, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) increased by 84.0% year-over-year, from $3.73M to $6.86M.
- What is the long-term trend for BioSig Technologies, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Over 2 years (2023 to 2025), BioSig Technologies, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a 934.1% compound annual growth rate (CAGR), from $190K to $20.32M.
- What does total cash, cash equivalents, and restricted cash (inclusive) mean?
- The aggregate sum of all cash, cash equivalents, and restricted cash held by the company, including balances related to discontinued operations. This metric provides a comprehensive view of the company's immediate liquidity position and its ability to meet short-term obligations. It is a fundamental measure of financial health and operational flexibility.